AU2001266902A1 - High throughput screening of compounds for biological activity - Google Patents

High throughput screening of compounds for biological activity

Info

Publication number
AU2001266902A1
AU2001266902A1 AU2001266902A AU6690201A AU2001266902A1 AU 2001266902 A1 AU2001266902 A1 AU 2001266902A1 AU 2001266902 A AU2001266902 A AU 2001266902A AU 6690201 A AU6690201 A AU 6690201A AU 2001266902 A1 AU2001266902 A1 AU 2001266902A1
Authority
AU
Australia
Prior art keywords
biological activity
compounds
target
candidate compound
substrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001266902A
Inventor
Jill Elaine Haizlip
Diane Michele Ignar
Channa K Jayawickreme
Holly Kay King
James Arthur Liacos
Kirsten Mills
Jason J. Ruan
Howard Ray Sauls Jr.
Joel Edward Shaffer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2001266902A1 publication Critical patent/AU2001266902A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects

Abstract

A method for screening candidate compounds for an ability to modulate the biological activity of a target. The method includes the steps of providing a substrate comprising a target and an indicator, the substrate adapted for receiving a plurality of candidate compounds; contacting the substrate with a plurality of candidate compound samples in a manner wherein an identity of each candidate compound can be determined and wherein the candidate compounds in the candidate compound samples interact with the target in the substrate; detecting a signal, the signal produced by the indicator upon interaction between the target and a candidate compound; and identifying a candidate compound as a modulator of the biological activity of the target based upon an amount of signal produced.
AU2001266902A 2000-06-13 2001-06-13 High throughput screening of compounds for biological activity Abandoned AU2001266902A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21126800P 2000-06-13 2000-06-13
US60/211,268 2000-06-13
US29453101P 2001-05-30 2001-05-30
US60/294,531 2001-05-30
PCT/US2001/019033 WO2001096597A2 (en) 2000-06-13 2001-06-13 High throughput screening of compounds for biological activity

Publications (1)

Publication Number Publication Date
AU2001266902A1 true AU2001266902A1 (en) 2001-12-24

Family

ID=26906001

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001266902A Abandoned AU2001266902A1 (en) 2000-06-13 2001-06-13 High throughput screening of compounds for biological activity

Country Status (8)

Country Link
US (1) US20030219825A1 (en)
EP (1) EP1360495B1 (en)
JP (1) JP2004503249A (en)
AT (1) ATE359513T1 (en)
AU (1) AU2001266902A1 (en)
DE (1) DE60127867T2 (en)
ES (1) ES2284655T3 (en)
WO (1) WO2001096597A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004092903A2 (en) * 2003-04-09 2004-10-28 Discovery Partners International Spot finding algorithm using image recognition software
DOP2006000008A (en) * 2005-01-10 2006-08-31 Arena Pharm Inc COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
WO2007100618A2 (en) * 2006-02-23 2007-09-07 Atto Bioscience Novel cell-based phosphodiesterase assays
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
CN101949819B (en) * 2010-09-16 2013-05-01 北京优纳科技有限公司 Cell counting method based on image identification
WO2018194406A1 (en) * 2017-04-19 2018-10-25 주식회사 프로티나 Method and apparatus for analysis of protein-protein interaction
KR20180117529A (en) 2017-04-19 2018-10-29 주식회사 프로티나 Method for predicting drug responsiveness by protein-protein interaction analysis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138621A1 (en) * 1991-11-25 1993-06-17 Boehringer Ingelheim Int METHOD FOR SCREENING SUBSTANCES WITH MODULATING EFFECT ON A RECEPTACLE-RELATED CELLULAR SIGNAL TRANSMISSION PATH
US5670113A (en) * 1991-12-20 1997-09-23 Sibia Neurosciences, Inc. Automated analysis equipment and assay method for detecting cell surface protein and/or cytoplasmic receptor function using same
WO1996001426A1 (en) * 1994-07-01 1996-01-18 W.R. Grace & Co.-Conn. Hepatocyte test kit
AU5143096A (en) * 1995-03-31 1996-10-16 Novo Nordisk A/S Method for identifying biologically active substances by the ir effect on living cells
US5780258A (en) * 1996-09-04 1998-07-14 Tularik, Inc Drug screens for regulators of the expression of the obese gene
DE69824757T2 (en) * 1997-11-27 2005-10-20 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. IDENTIFICATION AND CHARACTERIZATION OF INTERACTIVE MOLECULES BY AUTOMATED INTERAGING PAIRING
US5976813A (en) * 1997-12-12 1999-11-02 Abbott Laboratories Continuous format high throughput screening
WO2000017643A2 (en) * 1998-09-18 2000-03-30 Cellomics, Inc. A system for cell-based screening
WO2001094332A1 (en) * 2000-06-02 2001-12-13 Regents Of The University Of California Profiling of protease specificity using combinatorial fluorogenic substrate libraries

Also Published As

Publication number Publication date
EP1360495B1 (en) 2007-04-11
WO2001096597A3 (en) 2003-09-12
DE60127867D1 (en) 2007-05-24
DE60127867T2 (en) 2008-01-17
WO2001096597A2 (en) 2001-12-20
ATE359513T1 (en) 2007-05-15
US20030219825A1 (en) 2003-11-27
ES2284655T3 (en) 2007-11-16
EP1360495A2 (en) 2003-11-12
JP2004503249A (en) 2004-02-05

Similar Documents

Publication Publication Date Title
WO2003036256A3 (en) Method and apparatus for increasing the dynamic range and accuracy of binding assays
ATE421697T1 (en) METHOD FOR IDENTIFYING COMPOUNDS AFFECTING TRANSMEMBRANE PROTEINS
WO2002000006A3 (en) Nucleic acid enzyme biosensor for ions
ATE461450T1 (en) USE OF CONTROL SURFACES FOR DETECTING INTERFERENCE SAMPLES IN A DETECTION PROCESS
DE69816663D1 (en) DEVICE FOR DETERMINING ANALYTICS IN SOLUTIONS
EP1325343A4 (en) Increasing throughput in an automatic clinical analyzer by partitioning assays according to type
DE60001406T2 (en) APPARATUS AND METHOD FOR PRECISE LOCALIZATION OF REACTION PLATES
AU2849300A (en) Methods and assay kits for detecting mononuclear cell phenotype
WO2004011607A3 (en) Reagent and method for determination of a substance using an immunoaggregator
CA2342767A1 (en) Multihued labels
WO1999055913A3 (en) Reduced complexity nucleic acid targets and methods of using same
AU4299800A (en) Method for assessing the risk of peptic ulcer, comprising the steps of determining quantitatively the concentrations of pepsinogen i (pgi) and gastrin-17 in a serum sample
AU2001266902A1 (en) High throughput screening of compounds for biological activity
WO2000070342A3 (en) Optical system analysis of cells
WO2009064006A1 (en) SCREENING METHOD UTILIZING NOVEL SUBSTRATE EphA7 FOR γ-SECRETASE
AU5572998A (en) Improving performance of binding assays by use of more than one label
WO2008050335A3 (en) Method and system for detecting a target within a population of molecules
FR2817349B1 (en) NEW METHOD FOR SCREENING MODULATORS OF THE BACTERIAL TRANSCRIPTION
ATE513058T1 (en) DISPLACEMENT ASSAY FOR DETECTING NUCLEIC ACID OLIGOMER HYBRIDIZATION EVENTS
WO2004013607A3 (en) Methods, devices and kits for multiplex blotting of biological samples from multi-well plates
AU2002312899A1 (en) Hybrid method for the production of carriers for analyte determination
MXPA05010062A (en) Method of screening for target ligands.
AU5649499A (en) Method of detecting thiol-containing compound
WO2004078783A3 (en) Enzymes involved in apoptosis
WO2001002598A3 (en) Screening for compounds modulating mitochondrial proton leak